MYOV vs. MORF, INSM, RVNC, GLPG, SDGR, XENE, CORT, NUVL, BHC, and SAGE
Should you be buying Myovant Sciences stock or one of its competitors? The main competitors of Myovant Sciences include Morphic (MORF), Insmed (INSM), Revance Therapeutics (RVNC), Galapagos (GLPG), Schrödinger (SDGR), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Nuvalent (NUVL), Bausch Health Companies (BHC), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical preparations" industry.
Myovant Sciences vs.
Morphic (NASDAQ:MORF) and Myovant Sciences (NYSE:MYOV) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
79.8% of Morphic shares are owned by institutional investors. Comparatively, 30.6% of Myovant Sciences shares are owned by institutional investors. 28.1% of Morphic shares are owned by insiders. Comparatively, 1.9% of Myovant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Morphic currently has a consensus price target of $70.33, suggesting a potential upside of 14.23%. Myovant Sciences has a consensus price target of $21.33, suggesting a potential downside of 20.93%. Given Morphic's stronger consensus rating and higher possible upside, equities analysts clearly believe Morphic is more favorable than Myovant Sciences.
Myovant Sciences received 140 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 61.78% of users gave Myovant Sciences an outperform vote while only 60.98% of users gave Morphic an outperform vote.
Morphic has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.
Myovant Sciences has a net margin of -48.47% compared to Morphic's net margin of -92.38%. Myovant Sciences' return on equity of 0.00% beat Morphic's return on equity.
In the previous week, Morphic had 8 more articles in the media than Myovant Sciences. MarketBeat recorded 8 mentions for Morphic and 0 mentions for Myovant Sciences. Morphic's average media sentiment score of 0.26 beat Myovant Sciences' score of 0.00 indicating that Morphic is being referred to more favorably in the media.
Morphic has higher earnings, but lower revenue than Myovant Sciences. Morphic is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Morphic beats Myovant Sciences on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MYOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Myovant Sciences Competitors List
Related Companies and Tools